P/E at 26.54 vs Industry's 34.22: What the Data Shows for Dr Reddys Laboratories Ltd

Valuation Picture: Discount Amid Sector Strength

The current P/E of 26.54 for Dr Reddys Laboratories Ltd stands well below the sector average of 34.22, suggesting the stock is trading at a 22.5% discount relative to its peers. This valuation gap is particularly striking given the sector’s robust earnings environment, where 14 out of 20 stocks have reported positive results recently, with only 2 posting negative outcomes. The discount could reflect market concerns over growth sustainability or competitive pressures, but it also raises the question of whether the stock is undervalued relative to its fundamentals — previously rated Buy, what is Dr Reddys Laboratories Ltd’s current rating?

Performance Across Timeframes: Mixed Momentum

Examining the performance data reveals a stock that has outperformed the broader market over multiple horizons. Over one year, Dr Reddys Laboratories Ltd gained 7.17%, contrasting with the Sensex’s decline of 7.08%. Year-to-date, the stock is up 4.89% while the Sensex is down 10.40%, reinforcing the relative strength. Even over three years, the stock’s 47.15% return surpasses the Sensex’s 22.17%. However, the short-term momentum is less convincing: the one-week return is slightly negative at -0.06%, and the one-month gain of 1.32% is modest compared to the sector’s mixed performance. This divergence between short and long-term returns — is this a temporary pause or a sign of shifting momentum? — warrants attention.

Moving Average Configuration: Bullish Technical Setup

Technically, Dr Reddys Laboratories Ltd is trading above all major moving averages — the 5-day, 20-day, 50-day, 100-day, and 200-day. This comprehensive positioning indicates a strong upward trend and suggests that recent price action is supported by sustained buying interest. Being just 3.59% below its 52-week high of ₹1,377.95 further underscores the stock’s resilience. The alignment above short and long-term averages contrasts with the modest short-term returns, highlighting a technical strength that may not yet be fully reflected in price gains — is this a genuine recovery or a dead-cat bounce?

Sector Context: Pharmaceuticals & Biotechnology Holding Firm

The Pharmaceuticals & Biotechnology sector has demonstrated solid earnings momentum, with 14 of 20 stocks reporting positive results in the latest quarter. This sector-wide strength contrasts with the modest valuation of Dr Reddys Laboratories Ltd, which may be viewed as a relative laggard on price multiples despite its large-cap status and market cap of ₹1,11,276.47 crores. The sector’s positive earnings environment suggests that the stock’s valuation discount is not due to broad sector weakness but rather company-specific factors — should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider?

Rating Context: Previously Rated Buy, Now Reassessed

MarketsMOJO had previously assigned a Buy rating to Dr Reddys Laboratories Ltd, with a Mojo Score of 58.0. The rating was updated on 4 May 2026, reflecting a reassessment of the stock’s fundamentals and technicals. While the current rating is not disclosed, the data-driven approach highlights the tension between valuation discount and relative performance. The stock’s ability to outperform the Sensex over one year and maintain a strong technical position above all major moving averages contrasts with its lower P/E multiple and subdued short-term returns — what is the current rating for Dr Reddys Laboratories Ltd?

Long-Term Returns: Outperformance with Nuance

Over a three-year horizon, Dr Reddys Laboratories Ltd has delivered a 47.15% return, more than double the Sensex’s 22.17%. However, the five-year return of 26.13% trails the Sensex’s 49.67%, and the ten-year return of 115.71% lags the Sensex’s 189.60%. This pattern suggests that while the stock has demonstrated strong medium-term growth, it has underperformed over longer periods. The recent upward technical momentum and valuation discount may reflect a transitional phase in the stock’s performance cycle.

Short-Term Stability Amid Market Volatility

On the daily front, Dr Reddys Laboratories Ltd recorded a marginal gain of 0.08%, outperforming the Sensex’s decline of 0.17%. The stock opened at ₹1,330.15 and traded steadily at this level, indicating a stable intraday range. This steadiness, combined with the stock’s position near its 52-week high, points to a resilient price base despite broader market fluctuations.

Conclusion: Valuation Discount Meets Technical Strength

The data on Dr Reddys Laboratories Ltd reveals a complex interplay between valuation, performance, and technical indicators. Trading at a significant discount to its sector P/E, the stock has nonetheless outperformed the Sensex over one year and maintains a bullish technical stance above all major moving averages. The short-term momentum is modest, but the overall trend suggests resilience. The reassessment of the rating from a previous Buy reflects these mixed signals — should investors hold, buy more, or reconsider their position in Dr Reddys Laboratories Ltd?

53% Discount is LIVE - Get MojoOne + Stock of the Week for 3 Years Start Today